PTC Therapeutics, Inc. Stock: price and insider trades · United States

PTC Therapeutics, Inc. (NASDAQ: PTCT) is a U.S.-listed biopharmaceutical company headquartered in Warren, New Jersey, United States. For international investors, PTC is best understood as a rare-disease specialist with a commercial and R&D franchise focused on neurology and metabolic disorders. The company was founded in the late 1990s; SEC records show a name change date of 1998, consistent with its long operating history in rare-disease drug development. Over time, PTC has built a portfolio designed around high-unmet-need indications, where clinical differentiation and regulatory execution can be more important than broad primary-care scale. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1070081/000110465926017575/tmb-20251231x10k.htm?utm_source=openai))

PTC’s current investment case is driven by a combination of marketed products and a diversified pipeline. Its commercial portfolio has historically included Emflaza (deflazacort) and Translarna (ataluren), both important in the rare-disease space, although those franchises have faced headwinds from generic competition in Emflaza and adverse regulatory developments in Europe for Translarna. More recently, the company has expanded its growth platform with Sephience (sepiapterin) for phenylketonuria, or PKU. Sephience received key approvals in 2025 in the United States, the European Economic Area, and Japan, followed by approval in Brazil in February 2026. PTC also markets Upstaza/Kebilidi in certain geographies. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1070081/000110465926017575/tmb-20251231x10k.htm?utm_source=openai))